Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)
Saudi Arabia · Delayed Price · Currency is SAR 137.20
+2.60 (1.93%)
Sep 3, 2026, 3:14 PM AST
TADAWUL:4015 Ratios and Metrics
Market cap in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9,604 | 9,961 | 10,654 | 8,050 | - | - | |
Market Cap Growth | -12.50% | -6.50% | 32.35% | - | - | - |
Enterprise Value | 9,358 | 9,795 | 10,534 | 7,954 | - | - |
Last Close Price | 137.20 | 137.92 | 144.49 | 106.94 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 19.98 | 21.48 | 29.88 | 27.53 | - | - |
Forward PE | 18.80 | 20.02 | 25.61 | 25.41 | - | - |
PS Ratio | 6.10 | 6.64 | 8.08 | 7.31 | - | - |
PB Ratio | 5.11 | 5.80 | 7.15 | 5.73 | - | - |
P/TBV Ratio | 5.16 | 5.86 | 7.20 | 5.79 | - | - |
P/FCF Ratio | 26.29 | 28.20 | 51.60 | 32.10 | - | - |
P/OCF Ratio | 22.87 | 24.52 | 40.46 | 27.20 | - | - |
PEG Ratio | 2.12 | 1.43 | 1.60 | 1.01 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.95 | 6.53 | 7.99 | 7.23 | - | - |
EV/EBITDA Ratio | 16.80 | 18.94 | 24.82 | 23.28 | - | - |
EV/EBIT Ratio | 18.39 | 20.62 | 27.16 | 25.19 | - | - |
EV/FCF Ratio | 25.62 | 27.73 | 51.02 | 31.72 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.04 | 0.03 | 0.00 | 0.01 | 0.01 | 0.01 |
Debt / FCF Ratio | 0.06 | 0.05 | 0.01 | 0.01 | 0.02 | 0.02 |
Net Debt / Equity Ratio | -0.13 | -0.20 | -0.17 | -0.20 | -0.12 | -0.12 |
Net Debt / EBITDA Ratio | -0.45 | -0.66 | -0.61 | -0.84 | -0.54 | -0.72 |
Net Debt / FCF Ratio | -0.67 | -0.97 | -1.26 | -1.15 | -1.01 | -1.47 |
Asset Turnover | 0.71 | 0.79 | 0.77 | 0.72 | 0.65 | 0.50 |
Inventory Turnover | 2.38 | 2.18 | 1.98 | 2.18 | 2.44 | 1.97 |
Quick Ratio | 3.63 | 4.36 | 3.65 | 3.58 | 4.16 | 3.90 |
Current Ratio | 4.44 | 5.53 | 5.10 | 5.04 | 5.42 | 5.06 |
Return on Equity (ROE) | 27.00% | 28.92% | 24.63% | 22.32% | 14.00% | 14.16% |
Return on Assets (ROA) | 14.13% | 15.56% | 14.15% | 12.89% | 10.67% | 7.93% |
Return on Invested Capital (ROIC) | 29.59% | 34.32% | 30.80% | 26.73% | 20.71% | 16.05% |
Return on Capital Employed (ROCE) | 25.10% | 26.10% | 24.70% | 21.40% | 18.90% | 14.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.00% | 4.66% | 3.35% | 3.63% | - | - |
FCF Yield | 3.80% | 3.55% | 1.94% | 3.12% | - | - |
Dividend Yield | 3.27% | 2.90% | 2.12% | 2.34% | - | - |
Payout Ratio | 58.26% | 52.22% | 60.87% | 23.94% | 86.85% | 66.40% |
Buyback Yield / Dilution | - | - | - | - | -600.00% | - |
Total Shareholder Return | 3.27% | 2.90% | 2.12% | 2.34% | -600.00% | - |